AbbVie Target of Unusually Large Options Trading (ABBV)
AbbVie Inc (NYSE:ABBV) saw unusually large options trading on Wednesday. Stock investors acquired 159,063 call options on the stock. This represents an increase of approximately 1,953% compared to the average volume of 7,746 call options.
Shares of AbbVie (ABBV) opened at $100.34 on Friday. The stock has a market capitalization of $159,950.00, a PE ratio of 24.35, a P/E/G ratio of 1.20 and a beta of 1.53. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. AbbVie has a 1 year low of $59.27 and a 1 year high of $101.28.
AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. During the same period last year, the firm earned $1.21 EPS. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. research analysts anticipate that AbbVie will post 5.55 earnings per share for the current year.
In other AbbVie news, insider Henry O. Gosebruch sold 18,300 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the sale, the insider now owns 81,287 shares in the company, valued at approximately $7,360,537.85. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the company’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total value of $20,512,323.93. Following the sale, the chairman now owns 492,030 shares in the company, valued at approximately $46,255,740.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 494,676 shares of company stock worth $47,237,938. 0.23% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Capital Research Global Investors lifted its holdings in shares of AbbVie by 1.2% in the 2nd quarter. Capital Research Global Investors now owns 178,274,835 shares of the company’s stock valued at $12,926,708,000 after buying an additional 2,130,919 shares during the period. Vanguard Group Inc. lifted its holdings in shares of AbbVie by 3.3% in the 2nd quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock valued at $8,405,409,000 after buying an additional 3,706,941 shares during the period. BlackRock Inc. lifted its holdings in shares of AbbVie by 2.0% in the 2nd quarter. BlackRock Inc. now owns 94,074,962 shares of the company’s stock valued at $6,821,375,000 after buying an additional 1,864,418 shares during the period. Orbis Allan Gray Ltd lifted its holdings in shares of AbbVie by 35.7% in the 2nd quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock valued at $921,233,000 after buying an additional 3,340,038 shares during the period. Finally, Woodford Investment Management Ltd lifted its holdings in shares of AbbVie by 8.6% in the 2nd quarter. Woodford Investment Management Ltd now owns 11,854,758 shares of the company’s stock valued at $859,589,000 after buying an additional 937,500 shares during the period. 69.18% of the stock is owned by institutional investors and hedge funds.
ABBV has been the topic of several recent research reports. Societe Generale upped their price target on AbbVie in a report on Tuesday, November 21st. Jefferies Group restated a “buy” rating and set a $107.00 price target (up previously from $94.00) on shares of AbbVie in a report on Friday, September 15th. Piper Jaffray Companies restated a “buy” rating and set a $100.00 price target on shares of AbbVie in a report on Friday, September 15th. Argus upped their price target on AbbVie from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Finally, Zacks Investment Research upgraded AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price objective on the stock in a report on Tuesday, October 17th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $100.94.
WARNING: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/13/abbvie-target-of-unusually-large-options-trading-abbv.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.